PTP1B inhibition suggests a therapeutic strategy for Rett syndrome

Navasona Krishnan,1 Keerthi Krishnan,1 Christopher R. Connors,2 Meng S. Choy,2 Rebecca Page,2 Wolfgang Peti,2 Linda Van Aelst,1 Stephen D. Shea,1 and Nicholas K. Tonks3

1Cold Spring Harbor Laboratory (CSHL), Cold Spring Harbor, New York, USA. 2Department of Molecular Pharmacology, Physiology and Biotechnology, and 3Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, Rhode Island, USA.

The X-linked neurological disorder Rett syndrome (RTT) presents with autistic features and is caused primarily by mutations in a transcriptional regulator, methyl CpG–binding protein 2 (MECP2). Current treatment options for RTT are limited to alleviating some neurological symptoms; hence, more effective therapeutic strategies are needed. We identified the protein tyrosine phosphatase PTP1B as a therapeutic candidate for treatment of RTT. We demonstrated that the PTP1B gene, which encodes PTP1B, was a target of MECP2 and that disruption of MECP2 function was associated with increased levels of PTP1B in RTT models. Pharmacological inhibition of PTP1B ameliorated the effects of MECP2 disruption in mouse models of RTT, including improved survival in young male (Mecp2–/−) mice and improved behavior in female heterozygous (Mecp2+/−) mice. We demonstrated that PTP1B was a negative regulator of tyrosine phosphorylation of the tyrosine kinase TRKB, the receptor for brain-derived neurotrophic factor (BDNF). Therefore, the elevated PTP1B that accompanies disruption of MECP2 function in RTT represents a barrier to BDNF signaling. Inhibition of PTP1B led to increased tyrosine phosphorylation of TRKB in the brain, which would augment BDNF signaling. This study presents PTP1B as a mechanism-based therapeutic target for RTT, validating a unique strategy for treating the disease by modifying signal transduction pathways with small-molecule drugs.

Introduction

Rett syndrome (RTT) is a neurological disorder that affects approximately 1 in 10,000 female births (1), an incidence similar to that of cystic fibrosis and Huntington’s disease. Girls with RTT develop normally during the first 6 months of life but then begin to present a host of neurodevelopmental abnormalities including learning disabilities, loss of motor skills, stereotypic hand movements, irregular breathing, and seizures (1, 2). Boys are more severely affected and tend not to survive infancy due to encephalopathy (3). Patients with RTT also exhibit deficits in social interactions, a feature reminiscent of autism.

In over 95% of cases, RTT is caused by mutations in the X-linked methyl CpG-binding protein 2 (MECP2) gene, which was the first autism spectrum disorder gene to be identified (4). MECP2 is an epigenetic factor that binds to methylated DNA to regulate chromatin structure and the expression of a wide range of genes throughout the genome (5, 6). Although there are recognizable methyl CpG-binding and transcription repression domains, MECP2 is predominantly an intrinsically disordered protein that participates in a variety of protein-protein interactions and is subject to various posttranslational modifications, all of which contribute to its functional diversity (6). Hundreds of pathogenic MECP2 mutations have been identified, approximately half of which are associated with the methyl CpG-binding domain, focusing attention on its function as a regulator of gene expression (6). Mice lacking an intact Mecp2 gene have been shown to recapitulate a broad spectrum of phenotypes with similarities to those encountered in RTT patients (7–9). As in human patients, deficits are more pronounced in males than in females, with hemizygous null males being more severely affected by encephalopathy (7). In the heterozygous female (Mecp2+/−) mice, random X chromosome inactivation results in mosaic expression of MECP2 in the brain, with some cells expressing the mutant and others the normal allele, which likely contributes to phenotypic variations.

At present, these broad effects of MECP2 represent a challenge for drug development, and there is no disease-modifying therapy for RTT; instead, the focus has been on managing symptoms (1, 10). RTT has been associated with structural changes in the brain including reduced size and weight, together with effects on neuronal density and cell morphology (1, 2). Such abnormalities have often been viewed as irreversible; however, there have been studies to show that after disease onset in mice lacking the gene, restoration of MECP2 expression can rescue most neurological deficits and improve survival (7). This indicates that symptoms associated with Mecp2 loss can be reversed, focusing attention on reversible effects on neural circuits rather than on irreversible effects on development. There has been discussion in the field of future gene therapy approaches based on restoration of MECP2 function; however, considering the broad effects of MECP2 on the regulation of chromatin structure and gene expression and the important role of MECP2 in postmitotic neurons, it is unlikely that such approaches will provide an immediate solution. Instead, the field has begun to consider signaling events that may be subject to the influence of MECP2.

Related Commentary: p. 2931

Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: December 4, 2014; Accepted: June 5, 2015.
Reference information: J Clin Invest. 2015;125(8):3163–3177. doi:10.1172/JCI80323.
The neurotrophic factor brain-derived neurotrophic factor (BDNF) was identified as a target of MECP2, the levels of which are decreased in RTT. Experimental approaches to elevate BDNF ameliorated some symptoms (11), and alternative approaches using BDNF mimetics are being tested (12); however, the therapeutic utility of these mimetics remains to be established. Levels of insulin-like growth factor 1 (IGF-1) are also reduced in Mecp2-mutant mice (13), and treatment with an N-terminal tripeptide derived from IGF-1 has been reported to ameliorate some symptoms of RTT in these animals (13). In fact, these agents have formed the basis of clinical trials for this indication (13). In an alternative approach involving mutagenesis screens in Mecp2-mutant mice, mutations in squalene epoxidase, the rate-limiting enzyme in cholesterol biosynthesis, were identified as suppressing RTT-associated phenotypes. Interestingly, cholesterol metabolism is altered and cholesterol levels are elevated in the brains of Mecp2–/– male mice, all of which prompted the testing of statins with positive effects on some, but not all, categories of symptoms (14). Loss of function of MECP2 has also been associated with disruption of signaling through the AKT/mTOR pathway (15). Activation of this classical signaling pathway by adding exogenous growth factors or by suppressing the tumor suppressor PTEN ameliorated the effects of loss of MECP2 in neuronal cell models, suggesting that there may be beneficial effects of manipulating cell signaling to promote protein synthesis (15).

Instead of considering RTT in terms of alterations of specific driver genes, we looked at common phenotypic features that may suggest therapeutic targets. We noted that obesity and leptin resistance have been reported in some mouse models (16). In addition, insulin resistance has also been noted in some RTT patients (17). Furthermore, obesity is becoming recognized as a common feature of autism spectrum disorders (18). We further investigated this aspect of metabolic disruption in RTT and demonstrated that glucose metabolism and insulin signaling in the brain were attenuated in Mecp2-mutant mice. This suggested to us the possibility of a role for the protein tyrosine phosphatase PTP1B, which is recognized as a major metabolic regulator that is known to attenuate both insulin and leptin signaling (19). PTP1B inhibits insulin signaling by dephosphorylating the β subunit of the insulin receptor (IR-β) and insulin receptor substrate 1 (IRS1), and attenuates leptin signaling by acting on the leptin receptor–associated tyrosine kinase JAK2 (19). Hence, it negatively regulates the downstream PI3K/AKT signaling pathway that is important for development and known to be attenuated in RTT models (15, 20).

In this study, we have demonstrated that the PTPNI gene, which encodes PTP1B, was a direct target of MECP2 and that PTP1B protein levels were dramatically increased in Mecp2–/– mutant mice and in fibroblasts derived from patients with RTT. We show that administration of small-molecule inhibitors of PTP1B to Mecp2-mutant mice restored glucose homeostasis and enhanced insulin-induced tyrosine phosphorylation and signaling in the brain. Treatment with PTP1B inhibitors dramatically extended the lifespan of Mecp2–/– male mice and improved the performance of Mecp2–/– female mice in behavioral assays. Finally, we demonstrated that PTP1B recognized TRKB as a direct substrate and that inhibition of PTP1B resulted in enhanced TRKB phosphorylation in the brains of Mecp2-mutant mice. Overall, through this study, we have validated PTP1B as a target for therapeutic intervention in RTT, offering a new strategy for treating this disease by modifying signal transduction pathways with small-molecule drugs.

Results

Insulin signaling and glucose metabolism were impaired in Mecp2-mutant mice. Metabolic dysregulation is associated with a number of neurodevelopmental disorders including RTT syndrome. Interestingly, it was previously noted that Mecp2–/y mice on a 129S6B6F1 background display an obese phenotype characterized by insulin resistance and increased serum levels of cholesterol and triglycerides (21); however, it is not clear whether disruption of Mecp2 gene function results in impaired insulin signaling. We performed glucose and insulin tolerance tests (GTT and ITT) in both male Mecp2–/y (P30) and female Mecp2–/– (P70) mice to examine whether insulin signaling was altered in mouse models of RTT. Both hemizygous male Mecp2–/– and heterozygous female Mecp2–/– mice exhibited glucose intolerance and cleared glucose at a slower rate than did the control WT mice (Figure 1A). Furthermore, unlike the WT mice, blood glucose levels in both Mecp2–/– and Mecp2–/– mice failed to respond normally to administration of insulin (Figure 1B). We also found that insulin and cholesterol levels were higher in both Mecp2–/– and Mecp2–/– mice compared with levels in their WT counterparts (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI80323DS1). Although glucose and insulin intolerance was observed in both male Mecp2–/– and female Mecp2–/– mice, it was more pronounced in male Mecp2–/– mice, which may reflect the difference in MECP2 expression levels.

To characterize this observation further, we examined the insulin-signaling response in both Mecp2–/– and Mecp2–/– mice. In the male Mecp2–/– mice, which are MECP2-null, insulin-induced tyrosine phosphorylation of IR-β and IRS1 was markedly attenuated compared with the response observed in WT animals (Figure 1C). Recruitment of phosphorylated IRS1 to a complex with the insulin receptor (IR) triggers activation of phosphatidylinositol 3-kinase (PI3K) and stimulation of downstream signaling molecules such as PKB/AKT, which results in the inactivation of glycogen synthase kinase-3 β (GSK3β), the translocation of glucose transporters, and glucose uptake (22). Therefore, we examined phosphorylation of the kinase AKT and additional downstream signaling components. In contrast to the WT mice, Mecp2–/– mice displayed diminished insulin-induced phosphorylation of AKT and its substrates FOXO and GSK3β. Although the signaling response to insulin was diminished in the MECP2-mutant mice, these animals had higher circulating levels of the hormone (Supplemental Figure 1A). These are features of a classical example of insulin resistance. Similar trends of reduced tyrosine phosphorylation of IR-β and IRS1, together with decreased activation of AKT, were observed in female Mecp2–/– mice (Figure 1D). Consequently, the data suggest that these RTT models may also feature a metabolic disorder characterized by impaired insulin signaling and aberrant glucose metabolism. One poten-
tional mechanism for this effect would be that loss of expression of MeCP2 resulted in an increase in the levels or activity of a protein tyrosine phosphatase that normally functions as an antagonist of insulin signaling. Therefore, we tested for the effects of MeCP2 loss on gene expression in the mouse forebrain to identify candidates that are implicated in the control of insulin signaling (Figure 2A) and glucose metabolism (Supplemental Figure 2A) and regulated by MECP2.

**Mecp2–mutant mice expressed elevated levels of PTP1B.** Total RNA was isolated from the forebrains of MeCP2+/− (null) mice and their WT littermates. Our analysis by quantitative PCR (qPCR) revealed 4 genes that were upregulated by greater than 1.5-fold and 5 genes that were downregulated in the insulin-signaling pathway in MeCP2+/− mice compared with WT mice (Figure 2A). Since we were interested in identifying potential therapeutic targets, we focused our attention on genes that were upregulated in the MeCP2−/− animals. One of the 4 genes that was upregulated was Ptpn1, which encodes PTP1B, a protein tyrosine phosphatase that has been validated as a negative regulator of signaling in response to insulin and leptin (19); consequently, we tested whether PTP1N was a direct target of MECP2.

We used a series of reporter plasmids in which the expression of luciferase is driven by elements of the PTPNI promoter (23, 24). Upon coexpression of the reporter plasmids containing different lengths of the PTPNI promoter sequence, together with either isofrom of MECP2 (MECP2-E1 and MECP2-E2), we observed that both isofroms of MECP2 suppressed PTPNI promoter activity (Figure 2B). Furthermore, unlike WT MECP2, expression of MECP2-R168X, a clinically relevant loss-of-functional mutant, did not suppress PTPNI promoter activity (Figure 2C and Supplemental Figure 2C). These data suggest that PTPNI was a direct target of MECP2.

To confirm that MECP2 interacts with the PTPNI promoter, we carried out ChIP and examined several genes encoding known regulators of insulin signaling. Of those genes tested by ChIP analysis, we observed that MECP2 bound to the PTPNI promoter (Supplemental Figure 2B). Finally, to determine whether the increase in Ptpn1 mRNA detected by qPCR correlated with the level of PTP1B protein in MeCP2-mutant mice, we subjected equal quantities of lysate from WT and MeCP2−/− animals, related with the level of PTP1B protein in mRNA detected by qPCR correlation whether the increase in promoter (Supplemental Figure 2B). Finally, to determine whether the increased levels of PTP1B were associated with a decrease in circulating levels of insulin and cholesterol (Supplemental Figure 5, A and B). These data suggest that CPT157633 was a selective, reversible, active site–directed inhibitor of PTP1B.

To strengthen the functional analysis and ameliorate concerns about off-target effects of CPT157633, we characterized a second inhibitor of PTP1B that would exert its effect on the enzyme by a different mechanism. In our search for potent and selective inhibitors of the enzyme, we identified compounds with a triterpene structure, several of which were found to be noncompetitive inhibitors of PTP1B (26). Of those compounds assayed, UA0713 was found to be the most potent inhibitor of PTP1B (Supplemental Figure 4A and ref. 27). We observed that UA0713 was a noncompetitive inhibitor of PTP1B that inhibited the enzyme with a K_i of 150 nM (Supplemental Figure 4, B and C). It inhibited PTP1B with selectivity compared with a panel of 8 phosphatases investigated (Supplemental Figure 4D). Taken together, we have 2 high-affinity inhibitors of PTP1B that are structurally distinct and inhibit the enzyme by 2 distinct mechanisms.

**Inhibition of PTP1B improved survival in MeCP2−/− mice.** To investigate the extent to which the enhanced levels of PTP1B that were associated with MeCP2 disruption could contribute to the RTT phenotype, we tested the effects of these 2 structurally and mechanistically distinct inhibitors of the phosphatase on WT and MeCP2−/− mice. Two weeks after initiating treatment, we tested serum glucose levels and observed that the glucose intolerance encountered in untreated animals was markedly reduced (Figure 4A). In addition, we noted a small increase in BW in MeCP2−/− mice that were administered CPT157633 compared with that seen in saline-treated mice (Figure 4B), together with a decrease in circulating levels of insulin and cholesterol (Supplemental Figure 5, A and B). These data suggest that PTP1B inhibition resulted in an overall improvement in metabolism. Most strikingly, we observed that treatment with PTP1B inhibitors led to an approximately 2-fold increase in survival of the MeCP2−/− mutant mice (Figure 4C). The median lifespan was increased to 75 days following CPT157633 treatment and to 95 days for UA0713-treated mice, compared with 40 days for saline-treated animals.

As expected, treatment with the PTP1B inhibitors resulted in enhanced tyrosine phosphorylation of both IR-β and IRS1, 2
Mecp2−/−-mutant mice (Figure 4E). Together, these data suggest that, as well as modifying insulin signaling and glucose homeostasis, inhibition of PTP1B may also alter additional signaling events that play a critical role in the RTT phenotype.

Inhibition of PTP1B ameliorated symptoms of RTT in Mecp2−/+ mice. As heterozygous female Mecp2−/+ mice are a closer reflection of RTT in humans than are male Mecp2-null mice, we also tested the inhibitors of PTP1B in these animals (32). As a first step, we tested the effects of CPT157633 administration on glucose homeostasis (Supplemental Figure 5, C–E), none were as effective as the PTP1B inhibitors in extending the lifespan of the Mecp2−/+ mice (Figure 4E). Together, these data suggest that, as well as modifying insulin signaling and glucose homeostasis, inhibition of PTP1B may also alter additional signaling events that play a critical role in the RTT phenotype.

Inhibition of PTP1B ameliorated symptoms of RTT in Mecp2−/+ mice. As heterozygous female Mecp2−/+ mice are a closer reflection of RTT in humans than are male Mecp2-null mice, we also tested the inhibitors of PTP1B in these animals (32). As a first step, we tested the effects of CPT157633 administration on glu-
cose homeostasis. Consistent with the observation in male mice, we observed that the glucose intolerance encountered in saline-treated female Mecp2–/– mice was ameliorated within 3 weeks of treatment with the inhibitor (Figure 5A). Consistently, we also saw an improvement in insulin signaling (Figure 5B). Therefore, we tested whether treatment with CPT157633 also had an impact on neural and behavioral symptoms in Mecp2–/– mice.

Paw clasping is a classic phenotype consistently observed in Mecp2–/– mice, and it is similar to the characteristic hand wringing that is commonly noted in patients with Rett (33). When lifted by the tail, WT mice extended their limbs, whereas, in contrast, Mecp2–/– mice clasped their front paws spontaneously for the entire length of time they were monitored, without any significant movement of the paws. Interestingly, Mecp2–/– mice that were administered CPT157633, showed a marked reduction in paw clasping, and extended their paws in a manner similar to that of WT animals (Figure 5C).

Regression of motor skills is also one of the common symptoms associated with Rett in patients and is also observed in Mecp2–/– mice. To test whether inhibition of PTP1B resulted in improved motor skills, we subjected saline- and CPT157633-treated WT and Mecp2–/– mice to a rotarod performance test. In comparison with WT mice, the Mecp2–/– mice showed lower levels of activity on the rotarod. In 4 successive trials of the WT mice, a dramatic improvement was observed in the time spent on the rotating rod, whereas no improvement was observed with the saline-treated Mecp2–/– mice. However, CPT157633-treated Mecp2–/– mice displayed a significant improvement in performance, although this was a partial restoration and did not achieve the WT levels of performance (Figure 5D). Furthermore, when CPT157633 treatment was stopped for 1 week and motor ability was re-tested, we observed that the improved motor ability that accompanied treatment was lost (Supplemental Figure 6A). This illustrates that the effects of CPT157633 are reversible and that prolonged treatment with the compound appears not to have adverse effects in these mice.

Finally, we examined maternal pup gathering, a natural social communication behavior. Proficiency in this behavior is achieved by experience-dependent learning in first-time mothers and virgin females cohoosed with a mother and her pups (34–36). There are several advantages to assessing pup-gathering behavior in this context. First, we observed that deficiencies in this behavior are particularly robust in female Mecp2–/– mice. Second, the behavior relies critically on the detection of ultrasonic distress vocalizations by the female caregiver (37–39). Therefore, it requires interpretation of social information, an ability that is impaired in humans with Rett.

Third, pup-gathering behavior has been functionally linked to the primary auditory cortex. Thus, pup-retrieval behavior is a robust and sensitive assay that assesses clinically relevant behavioral features and is mediated by a known neural circuit substrate. We tested the effect of PTP1B inhibition on the pup-retrieval behavior of both saline- and CPT157633-treated Mecp2–/– mice. Interestingly, when Mecp2–/– mice that had been treated with CPT157633 were subjected to the pup-retrieval paradigm, their latency — the time to gather pups back to the nest — improved (Supplemental Figure 6B). Collectively, the data illustrate that treatment with PTP1B inhibitors ameliorated the effects of disrupting MECP2 function in male and female mouse models of Rett.

Inhibition of PTP1B led to increased phosphorylation of TRKB, the receptor for BDNF. PTP1B has been validated as a major regulator of insulin and leptin signaling (19); however, as antidiabetic agents were insufficient to extend the lifespan of Mecp2–/– mutant male mice, we examined whether the beneficial effects of inhibition of PTP1B were associated with alteration of other pathways. We focused our attention on BDNF because of its role in sustaining several processes in the brain and the reports of efforts to improve BDNF signaling as an approach to addressing Rett (40–42).

First, we quantitated BDNF levels in the brain of WT and Mecp2–/– mutant mice. Although BDNF levels were decreased in both Mecp2–/– and Mecp2–/– mice compared with those in controls, BDNF was still present at 60% to 70% of the levels detected in the control WT mice (Figure 6, A and B). This was consistent with other reports (11, 43) and suggests that impaired BDNF signaling through its cognate receptor, rather than the loss of BDNF itself, may be a major contributing factor in these Rett models. Therefore, we examined the status of tyrosine phosphorylation and activation of the BDNF receptor tropomyosin-related kinase B (TRKB). We observed that tyrosine phosphorylation of TRKB was attenuated in saline-treated Mecp2–/– mice compared with that seen in the WT controls. In contrast, treatment with the PTP1B inhibitor CPT157633 resulted in enhanced tyrosine phosphorylation of TRKB in both WT and Mecp2–/– heterozygous female mice (Figure 6C).

In order to determine whether TRKB was a direct substrate of PTP1B, we investigated whether the PTP1B-D181A substrate-trapping mutant form of the phosphatase formed a stable complex with TRKB. Unlike the WT PTP1B enzyme, which dephosphorylates and releases the bound substrate, the substrate-trapping mutant PTP1B-D181A forms a stable complex with the bound substrate, which can be isolated and characterized (44). We generated brain lysates from PTP1B inhibitor–treated mice and incubated equal quantities of lysate with either WT or D181A substrate–trap-
Figure 2. Mecp2-mutant mice expressed higher levels of PTP1B. (A) Total RNA obtained from WT and Mecp2−/− mice was reverse transcribed and the cDNA used in qPCR analysis. The relative change in gene expression in the insulin-signaling pathway in Mecp2−/− mice forebrain compared with WT was measured and the data normalized to Gapdh expression (n = 3, data represent the mean ± SEM). (B) A series of reporter constructs containing different lengths of the PTPN1 promoter were expressed in HEK293T cells, together with control or MECP2-E1– or MECP2-E2–expressing plasmids. Expression of either isoform MECP2-E1 (light gray) or MECP2-E2 (dark gray) suppressed PTPN1 promoter activity (n = 3, data represent the mean ± SEM). (C) Reporter constructs of the PTPN1 promoter were expressed in HEK293T cells, together with control or WT MECP2– or R168X MECP2–expressing plasmids. Expression of R168X MECP2 (gray), unlike WT MECP2 (black), failed to suppress PTPN1 promoter activity (n = 3, data represent the mean ± SEM). (D) Immunoblots showing PTP1B levels in forebrain lysates obtained from Mecp2−/− and WT male mice; the same lysates were used to blot for MECP2 and the loading control actin. Graph shows quantitation of the immunoblots. All blots are representative of experiments performed 3 times. (E) Immunoblots showing PTP1B levels in forebrain lysates obtained from Mecp2−/+ and WT female mice; the same lysates were used to blot for MECP2 and the loading control actin. Graph shows quantitation of the immunoblots. All blots are representative of experiments performed 3 times. (F) Immunoblots showing PTP1B levels in control and RTT patient–derived fibroblasts; the same lysates were used to blot for the loading control actin. Graph shows quantitation of the immunoblots. All blots are representative of experiments performed 3 times.
Figure 3. Biochemical characterization of the PTP1B inhibitor CPT157633. (A) Chemical structure of CPT157633. (B) Lineweaver-Burk plot for PTP1B showing 1/rate versus 1/substrate at varying concentrations of CPT157633: 0 (white circles), 25 nM (black squares), 50 nM (black triangles), and 100 nM (black diamonds). The $K_i$ was calculated to be 45 nM ($n = 3$, data are representative of 3 independent experiments). (C) PTP1B inhibition by CPT157633 was characterized using $^{32}$P-RCML as a substrate. $^{32}$P-RCML (0-1 μM) was titrated against PTP1B (10 nM) in the absence and presence of CPT157633 (100 nM) ($n = 3$, data are representative of 3 independent experiments). (D) Phosphatase activity of a panel of PTPs (10 nM) was tested in the absence and presence of CPT157633 (100 nM) using pNPP (2 mM) as a substrate ($n = 3$, data are representative of 3 independent experiments). (E) Titration of CPT157633 resulted mainly in CSPs localized to the residues that compose the PTP1B active site. Combined $^1$H/$^15$N CSPs versus residues are shown, and the secondary structure of PTP1B is indicated. Blue indicates residues that are in fast exchange, and red indicates residues that broaden beyond detectability upon addition of CPT157633 or that were previously not assigned in the PTP1B free form of PTP1B. (F) Overlay of PTP1B (gray surface) bound to CPT157633 inhibitor (orange). CSPs that accompanied binding of CPT157633 to PTP1B are mapped on to the structure (pink). (G) Electrostatic interactions between the CPT157633 inhibitor and the PTP1B active site loop (electrostatic interactions are indicated by black dashed lines).
ping mutant forms of PTP1B. We observed that TRKB formed a
complex with the PTP1B-D181A substrate–trapping mutant, but
not with the WT, active form of the phosphatase (Figure 6D). Fur-
thermore, pretreatment of the PTP1B protein with pervanadate,
which disrupts the active site of the enzyme, prevented binding to
TRKB. These data are consistent with TRKB being a direct sub-
strate of PTP1B.

Our previous structural studies highlighted the importance of
an Asp/Glu–p-Tyr–p-Tyr–Arg/Lys sequence motif for optimal
substrate recognition by PTP1B (28). The BDNF receptor TRKB
contains such a motif in its activation loop (28); therefore, we
examined the site specificity of the effects of PTP1B on this PTK
using SH-SY5Y as a model system. In order to define which phos-
phorylation sites were targeted by PTP1B, we expressed WT and
mutant (Y705/706F, Y516F, and Y815F) forms of TRKB in
SH-SY5Y cells. In response to BDNF stimulation, we noticed that
the overexpressed TRKB was phosphorylated and activated only
when the activation loop autophosphorylation sites were intact
(Figure 6E). Lysates from cells expressing these various forms of
TRKB were incubated with the PTP1B-D181A substrate–trapping
mutant, which was then immunoprecipitated, and its interaction
with TRKB was monitored. We found that PTP1B-D181A formed
a stable complex with WT TRKB in response to BDNF stimulation.
Mutation of both the activation loop residues Y705 and Y706 to
phenylalanine (F) in TRKB abrogated this interaction (Figure 6F),
whereas PTP1B-D181A was able to form a stable complex when residues Y516 and Y815 were mutated to phenylalanine (Figure
6F). Collectively, these data establish a direct enzyme-sub-
strate interaction between PTP1B and phosphorylated Y705/706
(p-Y705/706) TRKB, the critical autophosphorylation sites that
ascribe to BDNF-induced signaling.

Consistently, CPT157633 treatment resulted in enhanced
tyrosine phosphorylation of Y705/Y706 TRKB in Mecp2−/− brain
(Figure 6G). We also looked at the phosphorylation status of the
2 closely related TRK receptors TRKA and TRKC in response to
CPT157633 treatment in brain lysates obtained from Mecp2−/− mice
(Figure 6, H and I). Interestingly, the effects of PTP1B inhibition
by CPT157633 on phosphorylation of TRKA or TRKC receptors
were less pronounced than those on TRKB. Therefore, the data
are consistent with a role of PTP1B as an inhibitor of BDNF/TRKB
signaling that can be overcome by specific small-molecule inhibi-
tors of the phosphatase and suggest a possible mechanism for
the effects of the PTP that we observed in the RTT mouse models.

Discussion

In this study, we have demonstrated that MECP2 normally
suppressed the expression of the protein tyrosine phosphatase
PTP1B and that disruption of MECP2 resulted in elevated levels
of this phosphatase in RTT models. Consequently, overexpress-
ion of PTP1B has the potential to be a specific marker of RTT,
suggesting that PTP1B may be an ideal therapeutic target. We
have shown that administration of small-molecule inhibitors of
PTP1B dramatically extended the lifespan of Mecp2−/−-null male
mice and improved neural and behavioral symptoms of Mecp2−/−
hyezygous female mice, illustrating that inhibition of the
phosphatase led to amelioration of some of the phenotypes in
these models of RTT. The data also identify PTP1B as a critical
phosphatase for attenuating BDNF-induced signaling through
the TRKB protein tyrosine kinase. This suggests that in RTT,
functional loss of MECP2 causes an increase in PTP1B expres-
sion, which may then serve as a barrier to shift the signaling
equilibrium more toward the inactive state of TRKB, resulting
in impaired BDNF signaling (Figure 7). Therefore, this study, for
the first time to our knowledge, presents PTP1B as a potential
mechanism-based therapeutic target for RTT.

PTP1B is recognized as an antagonist of insulin and leptin
signaling (19, 45). As Mecp2-mutant mice exhibited character-
stistics of both insulin and leptin resistance, we reasoned that
upregulation of PTP1B may be of importance in contributing to
disruption of the glucose homeostasis that accompanies Mecp2
mutation in these RTT models. Whole-body knockout of PTP1B
produced mice with enhanced insulin sensitivity and resistance
to obesity induced by a high-fat diet (19, 45). Subsequent tis-
sue-specific knockouts revealed that PTP1B in the brain plays
a major role in the control of body mass and adiposity (45). As
a regulator of signaling in response to leptin, a hormone that is
produced by adipose tissue and exerts its physiological effect
through signals in the hypothalamus that control appetite,
PTP1B plays a key role in food intake and BW (45). In addition,
leptin has been shown to facilitate the induction of long-term
potentiation by increased transmission through the NMDA recep-
tor (46), suggesting a potential role for leptin and PTP1B in
learning and memory. Patients with RTT have been shown to
display phenotypes that are consistent with abnormal function
of the hypothalamus (16). Furthermore, deletion of MECP2 in
Sim1-expressing neurons in the hypothalamus generated mice
that displayed enhanced response to stress and abnormal social
behavior. In addition, these animals were hyperleptinemic and
displayed increased BW and body fat deposition associated
with increased food intake (16). This phenotype suggests a
classical leptin-resistant state, as would be encountered in the
presence of elevated PTP1B, consistent with a role for the phos-
phatase in contributing to RTT pathogenesis. Interestingly,
plasma levels of leptin have also been shown to be markedly
elevated in patients with RTT (47, 48), which is one of the hall-
marks of leptin resistance that is observed in metabolic disor-
ders. However not all patients with elevated leptin levels were
obese, which suggests that leptin accumulation in patients with
RTT could be related to factors other than weight control and
adiposity and that correcting circulating levels of leptin could
have a beneficial effect on other aspects of RTT.

The IR is distributed widely in the brain and has been impli-
cated in the control of synaptic function and dendritic architec-
ture, which suggests a role in the development and function of
neural circuits (49). Reduced insulin signaling in the brain has
been shown to contribute to impaired learning and memory,
resulting in cognitive deficits (49, 50). Interestingly, PTP1B is
expressed in hippocampal neurons, where it has been shown to
regulate learning behavior (51). Thus, antagonism of insulin sig-
naling, as would accompany conditions that promote elevated
PTP1B expression, may contribute to compromised learning
ability. Nevertheless, the observation that the antidiabetic agents
metformin, rosiglitazone, and AICAR restore glucose homeosta-
sis in Mecp2-null male mice, but unlike PTP1B inhibitors do not
extend lifespan, would suggest that the increase in PTP1B levels that we observed in Mecp2-mutant mice would be associated with suppression of other signaling pathways in addition to the response to insulin and leptin.

We demonstrated that PTP1B recognized TRKB as a direct substrate and that elevated PTP1B expression led to suppression of TRKB phosphorylation in Mecp2-mutant mice. Consistent with our observation, BDNF/TRKB signaling was recently shown to be augmented in the brains of PTP1B-knockout mice (52). This is of potential importance, because BDNF is also recognized as a target of MECP2 (42), thus implicating it in the etiology of RTT, and BDNF signaling is essential for various neuronal processes such as

---

**Figure 4. Inhibition of PTP1B with a small-molecule drug candidate ameliorated RTT phenotypes in male mouse models.** (A) Improved glucose homeostasis in CPT157633-treated Mecp2−/− mice compared with that in salinetreated mice, as monitored on P30 and P60 (n = 10). Statistical analysis was performed using 2-way ANOVA (P < 0.001). (B) Improved BW observed with CPT157633- and UA0713-treated Mecp2−/− mice compared with that of saline-treated mice (n = 10 per condition). Statistical analysis was performed using Student’s t test for the PTP1B inhibitor CEPTYR (P = 0.0033) and UA0713 (P = 0.0067). (C) PTP1B inhibition using CPT157633 (5 mg/kg) or UA0713 (5 mg/kg) improved survival in Mecp2−/− mice (n = 12 per condition). Comparison between PTP1B inhibitor- and saline-treated mice was performed using Student’s t test (P < 0.001). (D) Enhanced insulin signaling in Mecp2−/− mice upon CPT157633 treatment. Mecp2−/− compared with saline treatment (n = 4 per condition, all blots are representative of experiments performed 3 times, with 4 or more samples per condition). (E) No significant improvement in survival for Mecp2−/− mice was observed with metformin (50 mg/kg) (n = 10), AICAR (50 mg/kg) (n = 6), or rosiglitazone (25 mg/kg) (n = 6) administration. Student’s t test was used to evaluate the significance for metformin (P = 0.02), AICAR (P = 0.03), and rosiglitazone (P = 0.08).
cell survival, neurite growth, regulation of the inhibitory-excitatory balance, regulation of synapse formation, stabilization, and potentiation. BDNF signaling is initiated when the neurotrophic factor binds to the protein tyrosine kinase TRKB, the activation of which initiates important signaling responses (53). On the one hand, TRKB activation and tyrosine phosphorylation provide a docking site for the scaffolding protein SHC, which mediates activation of RAS/ERK and PI3K/AKT signaling pathways. On the other hand, TRKB activation recruits phospholipase-Cγ (PLCγ), which leads to mobilization of Ca\(^{2+}\) stores and activation of CaMKII and terminates in the activation of a transcriptional machinery initiated by the cAMP response element–binding (CREB) protein. Therefore, BDNF signaling through TRKB regulates translocation, protein translation through activation of the AKT/mTOR signaling pathway, and also mitogenic signaling through the RAS/MAPK signaling pathway (54). This would be consistent with an important role for PTP1B in multiple signaling contexts.

Although RTT is a monogenic disorder primarily caused by loss-of-function mutations in MECP2, there is a broad range of phenotypes associated with the myriad functions of MECP2. The search for phenotypic features in common in patients with RTT and in mouse models has illustrated the importance of metabolic changes, including disruption in mitochondrial function (55) and aberrant regulation of cholesterol metabolism (14). It is interesting to note that mice lacking PTP1B due to targeted disruption of the Ptpn1 gene display a positive lipid profile with reduced circulating triglycerides and cholesterol, even under high-fat diet conditions. Hence, it is tempting to speculate that the metabolic effects of pharmacological inhibition of PTP1B may also help to ameliorate these general symptoms associated with RTT pathology.
Figure 6. Inhibition of PTP1B led to increased phosphorylation of TRKB and enhanced signaling in response to BDNF. (A) BDNF levels measured by ELISA in the forebrains of P30 MeCP2-/- mice (gray bar) compared with WT animals (black bar) (n = 10, Student’s t test, P = 0.015). (B) BDNF levels measured by ELISA in the forebrains of 10-week-old MeCP2-/- mice (gray bar) compared with WT animals (black bar) (n = 10, Student’s t test, P = 0.023). (C) Tyrosine-phosphorylated proteins were immunoprecipitated from saline- and CPT157633-treated WT or MeCP2-/- mice, and immunoprecipitates were blotted for TRKB (upper panel). TRKB levels in each sample were measured by immunoblotting the lysate with anti-TRKB antibody (lower panel). (D) Brain lysates obtained from CPT157633-treated WT female mice were incubated with WT PTP1B or substrate-trapping mutant PTP1B-D181A, in the presence or absence of pervanadate. PTP1B immunoprecipitates were subjected to SDS-PAGE and immunoblotted with an antibody recognizing TRKB (upper panel) and PTP1B (lower panel). (E) WT and mutant forms of FLAG-TRKB were expressed in SH-SY5Y cells. Unstimulated and BDNF-stimulated cells were lysed and subjected to immunoprecipitation using anti-FLAG antibody. The immunoprecipitated samples were resolved on SDS gels and immunoblotted using the anti-phosphotyrosine antibody 4G10. (F) BDNF-stimulated lysates from SH-SY5Y cells expressing WT and mutant forms of TRKB were incubated with the substrate-trapping mutant form of PTP1B, and immunocomplexes were resolved on SDS gels and immunoblotted using anti-FLAG antibody to monitor the expression of TRKB. (G) Representative blot showing that CPT157633 treatment resulted in enhanced phosphorylation of Y705/Y706-TRKB on MeCP2-/- brain. (H) Representative blot showing the effects of CPT157633 treatment on tyrosine phosphorylation of the TRKA receptor in MeCP2-/- brain. (I) Representative blot showing the effects of CPT157633 treatment on tyrosine phosphorylation of the TRKC receptor in MeCP2-/- brain. All blots (C–I) are representative of experiments performed 3 times.
Current therapeutic strategies for treating RTT have largely focused on BDNF and IGF-1 signaling pathways, from the perspective of trying to increase the levels of the growth factors and thereby restore a normal signaling response (11, 13). Our data suggest that an approach from a different but complimentary perspective may be more beneficial. Although decreased levels of BDNF have been reported in mouse models of RTT, our data indicate that there remain substantial amounts of the neurotrophin; in fact, the MeCP2–/y mutant mouse models examined in this study maintain BDNF at 60% to 70% of WT levels. This is further supported by 2 reports, which show that BDNF levels in cerebrospinal fluid or in the serum of patients with RTT are comparable to levels in unaffected individuals (56, 57). Therefore, our data suggest that BDNF resistance and suppression of the signaling response to BDNF, due to elevated levels of the inhibitory phosphatase PTP1B, may be an important contributing factor to the etiology of RTT. Consequently, current strategies aimed at supplying higher levels of the growth factor stimulus are unlikely to be effective due to their inability to overcome the barier of elevated PTP1B. This is comparable to the situation in diabetes (insulin resistance) and obesity (leptin resistance), for which PTP1B is a validated therapeutic target. A better approach may be to alleviate the inhibitory constraint on the system by decreasing PTP1B activity with a small-molecule inhibitor, which would allow the cell to respond more effectively to available agonists.

Interestingly, when genetically defined autism candidate genes were ablated and transcriptomic analysis was conducted, it was observed that common signaling pathways were affected (58). This suggests that, despite the complex nature of autism spectrum disorders, with heterogeneity in behavioral and social impairments, there could be molecular mechanisms in common that may present an opportunity to target key regulatory checkpoints. Our new approach to therapeutic intervention in RTT using small-molecule drugs that target PTP1B and thereby targeting signaling pathways, including those that underlie metabolic regulation, also has implications for the treatment of other autism spectrum disorders and neurological diseases. For example, RAS/MAPK signaling has been identified as a regulator of activity-dependent protein synthesis, gene transcription, and mGluR-dependent synaptic plasticity, and disruption of the RAS/MAPK pathway has been associated with autism spectrum disorders (59, 60). Furthermore, metabolic disruption and obesity are becoming recognized as common features of autism spectrum disorders (18), suggesting that inhibition of PTP1B may also have a positive impact in those cases. Also, the utility of targeting PTP1B may not be restricted to autism spectrum disorders. For example, increased levels of PTP1B have been noted in a mouse model of Alzheimer’s disease (61). Furthermore, mutations in MeCP2 have been identified in other neurological diseases, such as schizophrenia (62), and it will be interesting to determine the extent to which this leads to alterations in PTP1B expression.

In conclusion, we have identified what we believe to be a novel therapeutic target and a novel strategy for the treatment of RTT. The identification of PTP1B as a therapeutic target highlights the possibility that some neurological disorders, such as RTT, may be viewed as reversible conditions that may be addressed through the manipulation of classical signaling pathways with small-molecule drugs. The prevalence of metabolic disruption and the importance of BDNF in other neuropsychiatric conditions, including autism spectrum disorders, further reinforces the potential to address a broad range of such conditions by this approach. With its extensive validation as a therapeutic target for treatment of diabetes and obesity, PTP1B has been the subject of drug development efforts for several years. Nevertheless, these efforts have been frustrated by technical challenges arising from the chemistry of PTP-mediated catalysis that have impeded the generation of inhibitors that target the active site but maintain appropriate pharmacokinetic and pharmacodynamic properties (19). However, this industry-imposed hurdle of oral bioavailability does not apply to all disease indications, including those for diseases such as RTT. Therefore, we hope that the results of this study will reinvigorate interest in PTP1B as a therapeutic target and open new opportunities to exploit this and other PTPs for the treatment of major human diseases.

Methods

Mice. B6.129-MeCP2<sup>tm1.1Bird</sup> J mice, purchased from The Jackson Laboratory (stock number 003890), were used in this study. CBA/CaJ mice were used in the pup-retrieval assays.

Drug administration. CPT157633 (CEPTYR Inc.) and UA0713 (The Chemistry Research Solution [TCRS] LLC) were dissolved in sterile saline solution and administered i.p. or s.c. CPT157633 was given at a single dose of 5 mg/kg BW every day, and UA0713 was given at a dose of 5 mg/kg every other day. With WT and MeCP2<sup>−/−</sup> male mice, compound administration was initiated at P2, and for WT and MeCP2<sup>−/−</sup> female mice, compound administration was initiated at 10 weeks of age.

Antibodies and reagents. All reagents were purchased from Sigma-Aldrich unless otherwise specified. The antibodies used to probe PTP1B in this study included ab 931 (Chemicon International) and 5600 (Cell Signaling Technology). The antibodies were used at a dilution of 1:500 and 1:1000, respectively.
in the study were directed against PTP1B (catalog 04-1140, clone EP1841Y; EMD Millipore); 4G10 (catalog 05-321, clone 4G10; Upstate Biotechnology); pY1162/1163-IR-β (catalog 700393, clone 97H9L7; Invitrogen); IR-β (catalog sc-711, clone C711; Santa Cruz Biotechnology Inc.); FLAG (catalog F3040, clone M1) and actin (catalog A2282, clone AC-74) (from Sigma-Aldrich); and IRS1 (catalog 2382, clone 59G8), p-T308 AKT (catalog 13038, clone D25E6), p-AKT (S473) (catalog 4051, clone 587F11), AKT (catalog 4691, clone C66E7), p-TFOXO1 (catalog 2599, clone 4G6), FOXO1 (catalog 2880, clone C29H4), p-GSK3β (catalog B452, clone D1G2), GSK3β (catalog 12456, clone D5C5Z), p-Y705/706 TRKB (catalog 4621, clone C50F3), pY515 TRKB (catalog 4619, clone C53G9), TRKB (catalog 4603, clone 80E3, and MECP2 (catalog 3456, clone D4F3) (all from Cell Signaling Technology). Control and RTT patient-derived fibroblasts were obtained from the Correlli repository. TRKA and TRKC expression constructs were a gift of Moses Chao (NYU Medical Center, New York, New York, USA).

Identification of TRKB as a substrate of PTP1B. Substrate identification experiments were performed as described previously (44). Brain lysates (1 mg/ml) obtained from saline- and/or PTP1B inhibitor–treated WT and MeCP2+/− female mice were incubated with 20 μl His-tagged WT PTP1B and PTP1B-D181A fusion protein coupled to beads (10 μg/μl) in the presence and absence of 1 μM perva- nome. After several washes, complexes were analyzed by immuno- blotting. SH-SYSY cells were cultured in DMEM supplemented with 10% FCS, 200 mM L-glutamine, nonessential amino acids (NEAA) (1×), and gentamycin (10 mg/ml; Invitrogen) at 37°C and 5% CO2 in a humidified atmosphere. Cells were differentiated by treatment with 10 μM retinoic acid for 7 days. These cells were used for all TRKB phosphorylation–related experiments by stimulating cells with varying concentrations of BDNF (0–100 ng/ml). PTP1B inhibitor (0–10 μM) treatment was performed for 1 hour prior to stimulation. For transfection of SH-SYSY cells, pFLAG-TRKB, pFLAG-Y515F TRKB, pFLAG-Y705F/Y706F TRKB, pFLAG-Y816F TRKB, and pCDNA-PTP1B were used. The TRKB constructs were a gift of James McNamara (Duke University, Durham, North Carolina, USA). Cells were seeded in 6-well plates at a density of 5 × 105 cells per well. After 24 hours, cells were transfected for 24 hours with FuGENE HD Transfection Reagent (Roche) according to the manufacturer’s protocol. Next, the cells were used for stimulation with BDNF, without or with PTP1B inhibitor treatment.

PTPN1 promoter assay. HEK293T cells were transfected using Lipofectamine Reagent (Life Technologies) according to the manufac- turer’s protocol. Typically, 1 μg of the reporter plasmid containing different lengths of the promoter was used along with 1 μg pRL- TK (Promega), an expression vector containing cDNA encoding Renilla luciferase, as an internal control for transfection efficiency. Approximately, 1.0 × 104 cells were used for each transfection with Lipofectamine Reagent (Life Technologies) in a 24-well plate. One microgram of the reporter plasmid for expression of firefly luciferase was used. Expression plasmids for either human MECP2-E1 (0.1 μg/ml), MECP2-E2 (0.1 μg/ml), or control plasmid without an insert (0.1 μg/ml) were cotransfected. Cells were incubated with a DNA-lipid complex for 24 hours and washed with PBS, and luciferase activity was assayed using the Dual-Luciferase Reporter Assay System (Promega).

Paw-clasping assay. For the paw-clasping assay, mice were sus- pended by their tails and observed for 30 seconds. The duration for which animals clasped their paws was used to calculate the percent- age (paw clasping [%] = [time spent clasping paws (s)/30(s)] × 100). Age-matched mice (MeCP2+/− vehicle-treated mice, n = 18; CPT157633- treated mice, n = 18) were used.

Rotarod performance. An increasing angular-speed rotarod system (AccuScan Instruments) was used on 12- to 14-week-old female mice. Both WT and MeCP2+/− mice were acclimated to the testing apparatus with three 90-second trials of steadily increasing speed (4–6 rpm). Following this acclimation, 4 trials were conducted. These trials were repeated the following day without an acclimation period. The latency to fall for each trial was recorded.

Protein expression and purification for NMR studies. The PTP1B catalytic domain (residues 1–301; PTP1B1–301) was expressed in E. coli and purified as previously described (63). Briefly, isotope-labeled PTP1B1–301 was expressed in E. coli cultures grown in M9 minimal media containing 1g/l 15N NH4Cl, 100% D2O, and either 4g/l 13C-D-glucose or 12C-D-glucose. Cultures were grown at 37°C to an OD600 of approximately 0.6 under vigorous shaking (250 rpm). Protein expression was induced with the addition of 1 mM isopropyl β-D-thiogalactopyranoside (IPTG), and cultures were incubated for approximately 20 hours at 18°C and shaken at 250 rpm. Protein yields were approximately 46 mg/l in Luria broth, approximately 34 mg/l in 1H,15N M9 medium, and approximately 17 mg/l in 1H,15N,13C M9 medium. Protein expression was Induced by Ni2+-affinity chromatography and size exclusion chromatography (SEC) (Superdex 75 26/60), with 50 mM HEPES, pH 6.8, 150 mM NaCl, 0.5 mM Tris [2-carboxylethyl] phosphate (TECP) as the final NMR buffer.

NMR spectroscopy. NMR data were collected on a Bruker AVANCE III HD 850 MHz spectrometer equipped with a TCI HCN Z-gradient cryoprobe at 298 K. NMR measurements of PTP1B1–301 were recorded using either 1H,15N- or 1H,15N,13C-labeled protein at a final concentration of 0.2 mM in 50 mM HEPES, pH 6.8, 150 mM NaCl, 0.5 mM TCEP, and 90% H2O/10% D2O. The sequence-specific backbone assignment of PTP1B1–301 in the CPT157633-bound state was achieved using the following experiments at 850 MHz 1H Larmor frequency: 2D [1H,15N] TROSY, 3D TROSY-HNCA, and 3D TROSY-HNCO/CA. Assignment and titration spectra were processed with Topspin 3.1 (Bruker), and data were evaluated using Sparky software (http://www.cgl.ucsf.edu/home/sparky/).

NMR analysis of inhibitor binding. CPT157633 was titrated into 200 μM [1H,15N]-PTP1B at molar ratios of 0.1:1, 0.2:1, 0.4:1, 0.5:1, 1:1, 1.5:1, 3:1, and 5:1. CPT157633 (PTP1B1–301 and 2D [1H,15N] TROSY spectra were recorded for each titration point. CPT157633 was solu- bilized in water at 100 mM. Chemical shift differences (DD) between PTP1B1–301 and CPT157633-bound PTP1B1–301 (1:5 molar ratio) spectra were calculated using the following equation:

\[
\Delta \delta (ppm) = \sqrt{\left(\Delta \delta_H \right)^2 + \left(\Delta \delta_\theta \right)^2} \times \frac{10}{10}
\]

(Equation 1)

All chemical shifts for CPT157633-bound PTP1B were deposited in the BioMagResBank (http://www.bmrb.wisc.edu) under accession number 253755.
Crystallization and structure determination. PTP1B<sub>1–301</sub> was purified as previously described (63), with the exception that the final protein buffer was 20 mM Tris, pH 7.5, 25 mM NaCl, 0.2 mM EDTA, and 0.5 mM TCEP. CPT157633 (10:1 molar ratio) was added to PTP1B to form PTP1B<sub>1–301</sub>:CPT157633, and the protein:ligand complex was concentrated to 50 mg/ml for crystallization. Crystals of PTP1B<sub>1–301</sub>:CPT157633 were obtained using sitting-drop vapor diffusion in 0.1 M Tris, pH 7.4, 20% PEG 8000, and 0.2 M MgCl$_2$. The small initial crystals were used as seeds for subsequent crystallization trials in the same mother liquor. Crystals were cryoprotected by a 10-second soak in mother liquor, supplemented with 30% glycerol and 10% CPT157633 (100 μM) and immediately flash-frozen in liquid nitrogen. X-ray data were collected on a single crystal at 112 K using a Rigaku FR-E+ SuperBright rotating anode x-ray generator with a Saturn 944 HG CCD detector (Brown University Structural Biology Facility), and the data were processed to 1.9 Å. The PTP1B<sub>1–301</sub>:CPT157633 data were phased using molecular replacement (Phaser, as implemented in PHENIX; ref. 64), with PTP1B (PDB ID: 1C88; ref. 65) as the search model. Clear electron density for the bound CPT157633 was visible in the initial maps. The initial model of PTP1B<sub>1–301</sub>:CPT157633 was built using Phenix.AutoBuild (64), followed by iterative rounds of refinement in PHENIX and manual building using Coot (66). The restraint file for the CPT157633 ligand was generated with Phenix.eLBOW (64) using the CPT157633 smiles string CNC(=O)[C@H].

Restraint file for the CPT157633 ligand was generated with Phenix.eLBOW (64) using the CPT157633 smiles string CNC(=O)[C@H] (C(=O)=C(F)(=O)(=O)O)c(=O)(Br)c1N5c(=O)=O. Data collection and refinement statistics are reported in Supplemental Table 2. All coordinates for CPT157633-bound PTP1B were deposited in the Protein Data Bank (PDB) under accession number 4Y14.

**Statistics.** All results are expressed as the mean ± SEM. ANOVA and a 2-tailed Student’s t test were used to determine statistical significance. A P value of 0.05 or less was considered significant. Statistical analysis and generation of graphs were performed using GraphPad Prism, version 7 (GraphPad Software).

**Study approval.** All study protocols involving mice were approved by the IACUC of the CSHL and conducted in accordance with NIH guidelines for the care and use of animals.

**Acknowledgments.** We thank Nick Pombonyo (summer student, Sacred Heart University, Fairfield, Connecticut, USA) for his help with the ChIP-PCR analysis. This research was supported by NIH grants CA53840 and GM55989 (to N.K. Tonks); NIH grant MH082808 (to L. Van Aelst); a CSHL Cancer Centre Support grant (CA45508); and by an American Diabetes Association Pathway to Stop Diabetes grant (1-14-ACN-31, to W. Peti). This research is based in part on data obtained at the Brown University Structural Biology Core Facility, which is supported by the Division of Biology and Medicine of Brown University.

Address correspondence to: Nicholas K. Tonks, Cold Spring Harbor Laboratory, 1 Bungtown Rd., Cold Spring Harbor, New York 11724, USA. Phone: 516.367.8846; E-mail: tonks@cshl.edu.
50. Mody N, Agoumi A, McIlroy GD, Platt B, Delibegovic M. Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1(A246E) mouse model of Alzheimer’s disease is associated with increased brain levels of protein tyrosine phosphatase IB (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein. Diabetologia. 2011;54(8):2143–2151.
61. Mody N, Agoumi A, McIlroy GD, Platt B, Delibegovic M. Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1(A246E) mouse model of Alzheimer’s disease is associated with increased brain levels of protein tyrosine phosphatase IB (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein. Diabetologia. 2011;54(8):2143–2151.